Home » CeNeS Updates M6G Program
CeNeS Updates M6G Program
UK’s CeNeS Pharmaceuticals has completed preparations for the U.S. Phase III program of M6G, a treatment for post-operative pain.
CeNeS has completed a Phase I pharmacokinetic study and a Phase I metabolism study. The company also has enrolled the final patient in its renal-impairment study.
The company said it expects to announce a licensing deal in 2008.
Upcoming Events
-
07May
-
14May
-
30May